Developing Next-Generation Organ and Tissue Perfusion

We are experts in perfusion. We are working with leading academic institutions to expand the possibilities for organ transplantation and developing innovative medical devices that will transform patient outcomes.

/ the passage of blood or other fluid through the blood vessels or other natural channels in an organ or tissue./”

Pre-clinical trials of the OrganBank have shown:

  • Perfusion can recover & preserve organs and tissues
  • Extending the time organs can remain viable for transplant to more than 24 hours
  • Therefore, extending the distance over which organs can be transported
  • reducing organ discards, saving thousands of lives

What we are up against

In 2021

105,800 people

were on the U.S.A. Waiting List


needed a kidney

Only 27%

on the list got them

Every 10 mins

a person is added to the wait list

3-5 years average

waiting time for a kidney

17 people die

each day on that wait list


30% of donated

kidneys were not transplanted

Globally only 10%

of the transplant need is accommodated

It’s Time for These Numbers to Change

Perfusion Research Expert Services

We offers access to advanced laboratory services to support biomarker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis to accelerate drug, vaccine and therapeutic development.


A self-contained organ preservation system, designed to support multiple organs at a time.

Our Company

BioMedInnovations was born through pressure controlled heart mimic experiments

Our Partners

Duquesne University
School of Pharmacy
Duke University
ExVivo Organ Lab (“DEVOL”)
RegenMed Development Organization (ReMDO)
Atrium Health,
Wake Forest Institute of Regenerative Medicine (“WFIRM”)
Department of Defense
Armed Forces Institute for Regenerative Medicine (AFRIM)
UNC Kidney Center
US National Lab
Department of Energy
Department of Neuroscience, Yale School Of Medicine, Sestan Lab
BMI is an NCBC portfolio company

Committed to making a difference for:


500,000 people in the U.S. – and three times that many globally – are on the organ waitlist and dialysis


Provide better instruments and ex vivo organ metrics with which to work and make critical, life-saving decisions


Last year nearly 30% of donated kidneys were not transplanted, and only 10% of the transplant need is accommodated globally


Transplants have the potential to bend down the cost curve since they are less expensive than dialysis